Nivolumab/ipilimumab combination extends treatment-free survival in kidney cancer patients

Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab have revolutionised the treatment for metastatic renal cell carcinoma (RCC). However, the most appropriate duration for immunotherapy treatment is not clear. In a recent analysis of the results from the phase III CheckMate 214 trial, all RCC patients randomised to receive the nivolumab/ipilimumab combination had longer […]

read more

Alternative schedule ipilimumab plus nivolumab for first-line treatment of advanced kidney cancer

The combination of nivolumab with ipilimumab has been proven to be effective in the treatment of patients with metastatic renal cell carcinoma (RCC), and is available as a first line treatment via the Cancer Drugs Fund in England and Wales. In the current UK-based study (PRISM), which is still ongoing, researchers are assessing whether less […]

read more

Comparison of first-line immunotherapy combinations for advanced kidney cancer

In this paper, three clinical trials with immunotherapy combinations for the first-line treatment of clear renal cell carcinoma (RCC) are discussed. Dr  Robert Motzer from Memorial Sloan Kettering Cancer Center in New York compared the findings from the three trials at the Annual Chemotherapy Foundation Symposium (CFS) in New York last week. All three phase […]

read more

ESMO 2019: Results from TITAN-RCC tailored immunotherapy clinical trial

Results from the TITAN-RCC clinical trial to assess tailored immunotherapy for patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. TITAN-RCC is a large phase 2 study investigating tailored immunotherapy for people with advanced RCC. Patients started with nivolumab monotherapy. The […]

read more

Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases

An interim analysis of study Checkmate 920 has shown that patients with advanced renal cell carcinoma (RCC) and brain metastases may benefit from treatment with the ipilimumab/nivolumab combination therapy. The results from this interim analysis were presented at the 2019 American Society of Clinical Oncology (ASCO) in Chicago earlier this month. Read more in Cancer […]

read more

SMC approves nivolumab plus ipilimumab combination for advanced RCC

We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of nivolumab plus ipilimumab for intermediate-/poor-risk advanced renal cell carcinoma (RCC) by NHS Scotland. The nivolumab (Opdivo) plus ipilimumab (Yervoy) combination was accepted following consideration through the SMC’s Patient and […]

read more

Predictive biomarkers in metastatic kidney cancer

A review published in European Urology Focus looks at tools to optimise the choice and sequence of treatments to ensure the best clinical benefit for their metastatic renal cell carcinoma (RCC) patients. The review concludes that the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model is currently the only validated tool that can […]

read more

First immunotherapy combination of ipilimumab plus nivolumab available to patients in England

We are very pleased to learn that the ipilimumab plus nivolumab combination has been endorsed for use by the National Institute for Health and Care Excellence (NICE) for poor- and intermediate-risk advanced renal cell carcinoma (RCC). The treatment will be made immediately available to patients in England via the Cancer Drugs Fund. The availability of […]

read more

ASCO GU 2019: Nivolumab-ipilimumab survival benefit in advanced kidney cancer

New 30-month survival data from the CheckMate 214 study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Additional 30-month follow-up data from the phase 3 CheckMate 214 trial confirms the survival benefit of the nivolumab plus ipilimumab combination over sunitinib as a first-line treatment for patients […]

read more

Nivolumab plus ipilimumab combination shows survival benefit for patients with untreated kidney cancer at 30 months

Further survival data has been released from the phase 3 CheckMate-214 study, showing that treatment with a combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to demonstrate long-term survival benefits in patients with previously untreated advanced/metastatic renal cell carcinoma (RCC) after 30 months follow-up. Patients with intermediate- and poor-risk untreated RCC treated with the nivolumab/ipilimumab […]

read more
Showing 1 to 10 of 50 results
  TOP